IMRX
Immuneering Corporation
5.05
2 x 3.64
2 x 6.29
bid
ask
+
0.06
1.20%
2 @ 08:50 AM
5.09 +0.04 (0.86%)
| Ytd | -23.25% | |
| 1y | 46.80% |
4.88
day range
5.17
2.90
52 week range
10.08
| Open | 5.02 | Prev Close | 4.99 | Low | 4.88 | High | 5.17 | Mkt Cap | 326.72M |
| Vol | 1.07M | Avg Vol | 1.51M | EPS | -1.06 | P/E | N/A | Forward P/E | -1.34 |
| Beta | -0.40 | Short Ratio | 1.19 | Inst. Own | 30.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 4.94 | 200-d Avg | 5.71 | 1yr Est | 12.42 |
| Income Statement | |||
| Operating Expenses | 15.34M | ||
| Research and Development Expense | 10.65M | ||
| Selling, General and Administrative Expense | 4.68M | ||
| Operating Income | -15.34M | ||
| Net Income | -13.46M | ||
| Net Income Common Stock | -13.46M | ||
| Net Income Common Stock (USD) | -13.46M | ||
| Consolidated Income | -13.46M | ||
| Earnings per Basic Share | -0.21 | ||
| Earnings per Basic Share (USD) | -0.21 | ||
| Earnings per Diluted Share | -0.21 | ||
| Earning Before Interest & Taxes (EBIT) | -13.46M | ||
| Earning Before Interest & Taxes (USD) | -13.46M | ||
| Weighted Average Shares | 64.66M | ||
| Weighted Average Shares Diluted | 64.66M | ||
| Balance Sheet | |||
| Cash and Equivalents | 47.32M | ||
| Cash and Equivalents (USD) | 47.32M | ||
| Investments | 151.32M | ||
| Investments Current | 109.37M | ||
| Investments Non-Current | 41.95M | ||
| Current Assets | 161.41M | ||
| Property, Plant & Equipment Net | 4.17M | ||
| Total Assets | 214.81M | ||
| Debt Current | 412.84K | ||
| Total Debt | 3.73M | ||
| Current Liabilities | 4.97M | ||
| Debt Non-Current | 3.32M | ||
| Total Liabilities | 8.29M | ||
| Accumulated Retained Earnings (Deficit) | -293.78M | ||
| Accumulated Other Comprehensive Income | -241.00K | ||
| Shareholders Equity | 206.52M | ||
| Shareholders Equity (USD) | 206.52M | ||
| Assets Non-Current | 53.40M | ||
| Total Debt (USD) | 3.73M | ||
| Goodwill and Intangible Assets | 7.00M | ||
| Liabilities Non-Current | 3.32M | ||
| Trade and Non-Trade Payables | 1.45M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 180.48K | ||
| Net Cash Flow from Financing | 180.76K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -81.32M | ||
| Capital Expenditure | -79.93K | ||
| Issuance (Purchase) of Equity Shares | 180.76K | ||
| Net Cash Flow from Investing | -63.07M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -62.99M | ||
| Net Cash Flow from Operations | -18.43M | ||
| Share Based Compensation | 1.64M | ||